SEC Tracker
Get the app
ALGS · XBRL financial data

Aligos Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ALGS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers1,085672*6941,0611,250606*311965741169*2,8300
Research and development15,86722,257*16,36621,09916,77416,031*14,50213,97623,93717,038*23,35224,050
General and administrative6,4436,421*6,6666,3764,6265,161*5,0525,5565,1654,945*6,4075,618
Total operating expenses22,31028,678*23,03227,47521,40021,192*19,55419,53229,10221,983*29,75929,668
Other operating income (expense)1,059(1,925)*(12,793)31,664963(15,428)*8801,2071,085750*811221
Operating income (loss)(19,071)(25,997)*(22,046)(26,414)(20,131)(20,563)*(19,243)(18,567)(28,361)(21,814)*(26,929)(1,890)
Income tax expense (benefit)29(30)*241899127*431855630*3172,811
Net income (loss)(18,041)(27,892)*(34,863)5,061(19,259)(82,150)*43,088(15,863)(31,537)(19,881)*(23,040)(1,504)
Earnings per share, basic‡ USD per share(10.25)—(5.50)0.75(3.07)(13.08)*5.12(1.53)(3.04)—(2.21)(0.14)
Earnings per share, diluted‡ USD per share(10.25)—(5.50)0.75(3.07)(13.09)*(2.11)(1.53)(3.04)—(2.21)(0.14)
Weighted average shares, basic‡ thousands of shares1,740—6,2466,2586,2726,282*8,40810,35110,37010,384*10,40310,431
Weighted average shares, diluted‡ thousands of shares1,740—6,2466,2666,2726,274*8,71010,35110,37010,089*10,40310,431
  • ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (ALGS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents70,429135,70424,15145,07835,33136,99773,76318,66141,94618,30329,98030,381
Short-term investments——88,58849,45839,59119,94264,098104,28457,15059,54124,9290
Accounts receivable———————————27,778
Total current assets74,643141,084118,06499,57079,82262,141143,205127,944103,43582,86259,62962,127
Property and equipment, net3,6463,2593,0462,7972,5752,3622,2142,0632,0351,8671,5901,334
Right-of-use asset6,9406,5596,1675,8135,3944,9644,6484,0593,5813,0892,5802,107
Total assets85,852151,527127,902108,81188,42670,094150,699134,706109,76488,53364,55866,327
Accounts payable2,9412,5172,8426,8192,7402,5714,4603,9374,6513,9827,6396,431
Accrued liabilities12,32216,84212,04312,06414,16115,55711,00112,20913,60513,52611,98918,696
Total current liabilities22,46823,90618,88023,56420,95621,73718,94820,26521,98721,23323,32228,343
Lease liability, non-current8,3297,6686,9946,2795,5454,7954,2653,2162,3801,525659288
Total liabilities31,03159,44768,10641,58238,33099,06734,25432,84037,93134,98832,76934,443
Accumulated deficit(458,905)(486,797)(521,660)(516,599)(535,858)(618,008)(574,920)(590,783)(622,320)(642,201)(665,241)(666,745)
Total stockholders' equity54,82192,08059,79667,22950,096(28,973)116,445101,86671,83353,54531,78931,884
Total liabilities and equity85,852151,527127,902108,81188,42670,094150,699134,706109,76488,53364,55866,327
Common shares outstanding (cover page)‡ thousands of shares1,7403,0043,0273,1913,3253,8646,1156,1516,1546,1786,1886,237
  • ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (ALGS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(18,041)(27,892)*(34,863)5,061(19,259)(82,150)*43,088(15,863)(31,537)(19,881)*(23,040)(1,504)
Stock-based compensation3,209*2,583*2,6482,056*2,043*1,705*9591,160*1,467*1,458*1,3141,364*
Net cash from operating activities(20,336)*(22,658)*(22,746)(19,493)*(20,101)*(18,403)*(20,909)(15,504)*(24,345)*(21,745)*(23,128)(24,950)*
Purchases of property and equipment—year only———year only——————
Net cash from investing activities(9)*(7)*(88,642)39,993*10,398*19,972*(44,067)(39,421)*47,683*(2,021)*34,93124,999*
Proceeds from issuing common stock—year only——————————
Net cash from financing activities(21)*87,936*(19)281*(4)*97*101,742(177)*(53)*123*(62)220*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Aligos Therapeutics30,3810(24,950)*6.2M1.2 quarters 10-QJun 30, 2026
CEL-SCI6,527not reported(4,031)*17.6M1.6 quarters 10-QJun 30, 2026
Relmada Therapeutics11,334not reported(9,606)*106.7M22.7 quarters 10-QJun 30, 2026
Fibrogen50,644(1,474)(3,991)*4.0M22.9 quarters 10-QJun 30, 2026
Armata Pharmaceuticals23,952not reported(8,666)*37.2M2.8 quarters 10-QJun 30, 2026
Imunon6,864not reported(3,025)*5.6M2.3 quarters 10-QJun 30, 2026
Lunai Bioworks1,71431*(1,841)*5.0M0.9 quarters 10-KJun 30, 2026
Dare Bioscience12,618188(6,775)*15.3M1.9 quarters 10-QJun 30, 2026
IGC Pharma331265(1,350)*103.4M0.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.